Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (251-260 of 302) with videos related to

Pageof 31
Sort By:
Blood Advances|October 24, 2018
High-resolution architecture and partner genes of <i>MYC</i> rearrangements in lymphoma with DLBCL morphologyLauren C Chong, Susana Ben-Neriah, Graham W Slack, et al.
International Journal of Cancer|June 12, 2013
Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological featuresAnna Enjuanes, Robert Albero, Guillem Clot, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2015
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell TransplantationHaowei Sun, Kerry J Savage, Aly Karsan, et al.
Cancer Discovery|February 2, 2019
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune RecognitionDaisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, et al.
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
The Lancet. Haematology|May 28, 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trialDavid J Straus, Monika Długosz-Danecka, Joseph M Connors, et al.
Blood|October 29, 2020
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHCBrett Collinge, Susana Ben-Neriah, Lauren Chong, et al.
British Journal of Haematology|September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvementTarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood|June 29, 2012
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphomaAnamarija M Perry, Teresa M Cardesa-Salzmann, Paul N Meyer, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Pageof 31

Showing results (251-260 of 302) with videos related to

Sort By:
Pageof 31
Blood Advances|October 24, 2018
High-resolution architecture and partner genes of <i>MYC</i> rearrangements in lymphoma with DLBCL morphologyLauren C Chong, Susana Ben-Neriah, Graham W Slack, et al.
International Journal of Cancer|June 12, 2013
Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological featuresAnna Enjuanes, Robert Albero, Guillem Clot, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2015
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell TransplantationHaowei Sun, Kerry J Savage, Aly Karsan, et al.
Cancer Discovery|February 2, 2019
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune RecognitionDaisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, et al.
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
The Lancet. Haematology|May 28, 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trialDavid J Straus, Monika Długosz-Danecka, Joseph M Connors, et al.
Blood|October 29, 2020
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHCBrett Collinge, Susana Ben-Neriah, Lauren Chong, et al.
British Journal of Haematology|September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvementTarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood|June 29, 2012
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphomaAnamarija M Perry, Teresa M Cardesa-Salzmann, Paul N Meyer, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Pageof 31